David Sinclair (Life Biosciences) OSK human trials is now live. We will see OSK being injected into humans in 2026

in my opinion, the new OSK research in recent 2 years have shown the risks u mentioned are mostly not present, though there remains more work to be done.

i def did not call it ‘the only real anti-aging technology’ in fact, i mentioned the reverse, that there are many other interesting research and applications.

OSK has been done in mice and primates and in primates it is safe and works as well. they are also doing it on human organoids and in vitro.

i dont take rapa, but it has been shown to can have serious side effects. if it works for you, great, i am happy.

i believe geroscience and medicine in general is undergoing not incremental breakthroughs but big breakthroughs currently. this is the opinion of david sinclair as well as many researchers and practitioners.

What serious side effects? Tell us your opinion on rapamycin.

Main side effect is mouth sore. It also can worsen blood sugar and cholesterol for some. It can slightly increase chance of catching a cold or flu.

Was that it?

Dunno i dont use it

U do? Feel free to share.

Its not avail over the counter here need a prescription and i have no interest in rapa personally.

There is literally hundreds of responses to this question on another thread. Just do a search and you’ll find plenty of answers. No need to repeat IMO.

This is also the rapamycin.news website and most people here take Rapamycin.

The side effects most people report are not serious.

I’ve had mouth sores a few times. That is all.

I generally feel good when I take Rapamycin.

3 Likes

Is there anything you do currently take?

Claims that we are close to doubling our average lifespans and just need to hang in there for a bit are so wrong they are dangerous and harmful for progress. There are far more limits that need to be overcome than just figure out how to use reprogramming therapies in vivo. Besides, even the reprogramming therapies are far away. We’re barely scratching the surface.

Yes he has had a large impact, much of it positive but not all impact is good. Awareness can be negative if it promotes hype and unreasonable expectations. So many older people that listen to him are going to think they have a chance of making it but they will be disappointed.

They didn’t live 100% longer. Their remaining lifespan was 100% longer. They started treatment in old age when the mice were 125 weeks old. Those given the therapy lived to about 145 weeks of age compared to control who lived to 135 weeks of age (so extra 20 weeks vs extra 10 weeks). That’s similar to treating 70 year olds humans with the therapy and seeing that they live to 80 while the controls live to 75. That’s an important benefit but nothing close to doubling lifespan or even getting close to the current maximum lifespan. Yes we would probably see larger benefits if treatment were started at younger ages, but I don’t think it would make a ton of difference. The benefits should be greaters at older ages since that’s when the cells are most in need of reprogramming.

3 Likes

They injected mouse about to die basically and only had 10 or 20 weeks to activate it 1 off 1 on.

So the timing of osk was limited only 1 or 2 months of osk treatment.

And its likely that they couldnt rejuvenate all cells full body in the experiment due to limited proliferation of osk

Yes but a lot of cells that didn’t get OSK activation from the gene therapy wouldn’t have gotten it even if you treated the mice with the therapy from a young age.

The OSK factors are transcription factors not cells. They do not replicate. What limits the delivery such that not all cells are reprogrammed is the viral vector delivery method. Those methods are not good enough to reach all the cells in the body.

Also there is another problem here. Different cells will require different amounts of reprogramming factors for reprogramming. Too much or too little could cause problems. There is no delivery method that can deliver different doses to different cells depending on what each cell needs. We don’t even have a way to measure the state of each individual cell in the body to determine the dose each one needs in the first place. That’s a ridiculously difficult problem to solve and we are nowhere close.

3 Likes

This is an order of magnitude more dangerous than Rapamycin IMO.

I do have a PhD in cell biology, run a lab, and we have two papers published using temporary reprogramming (OKSM) for regeneration, and have been invited to write a commentary on other reprogramming papers. So I’d call myself reasonably credible in this field.

With that said, I am quite surprised it’s going forwards in humans, in any capacity. Even without the c-Myc, I see this as a fairly risky approach which is not well established and there’s a huge amount we don’t know. For example, as @Olafurpall has alluded to, this is very sensitive to the dose, timing etc. Reprogram too much and cells lose their function, de-differentiate, and even become pluripotent and form tumours. That will be extremely detrimental. If you reprogram optic nerve cells too much, they will stop being nerve cells at all, and there’s no coming back from that.

However, I do believe in the scientific principle that a temporary, controlled, partial reprogramming can rejuvenate cells, because I’ve seen it with my own eyes in my lab and others.

Delivery is crazy difficult, and we can’t control which cells receive the reprogramming factors, or how much. You just kinda inject it around the area and cross your fingers. Most of the work is done in mouse models, and often we us genetically edited mice which can enable OSK(m) using drugs like doxycycline or tamoxifen - but those techniques are not applicable to humans. For humans, I assume they’re using AAV. We can try to develop some sort of specificity using promoter driven expression, but it’s still not well defined. It’s also extremely dependent on the type of cell, so what works well for an optic nerve neurone may not work for a muscle cell or a liver cell.

So yes, I think it’s very cool that people are pushing this forwards. But it has to be done very carefully. Racing ahead, taking too many risks etc could backfire spectacularly. If someone develops a nasty teratoma behind their eye the whole stem cell and reprogramming field will be tarnished for at least a decade. The last thing we need is some sort of celebrity hype man over-selling this.

9 Likes

Well said. I’ve read a lot of studies on reprogramming I agree with all you said about the difficulty and risks of such therapies at the current stage we’re at.

but david sinclair has done this OSK thing in mouse models and primates and no teratomas was detected

regarding the delivery issue, yes that is well known, he pointed it out himself it is a delivery issue to solve at this stage as OSK (without M) works. i assume it works well enough within organs but delivering full body is a big issue.

it rewinds the cell’s age to a certain point but does not go to pluripotency but still keeps it differentiated and young.

i wonder what your thoughts are on the above, given you are an expert at this and most of us on this forum are not.

We know enhanced autophagy has merits and SOX2 encourages enhanced autophagy. My issue with reprogramming is that it assumes that there is somewhere a backup copy of the program without identifying where it is. I do myself think there is a program and that the pointer in the program for any particular cell type is the level of nuclear acetylation in a non stressed cell (without hyperacetylation). However, that does not mean that dedifferentiating cells is a good idea.

I agree entirely with what you say.

1 Like

From the Shiftbioscience website:

SB000 expression does not induce pluripotency with absence of iPSC colonies (white dotted lines).

Hey, thanks for the question. I’m not familiar with the exact details of what Sinclair is doing to give really specific comments yet. Do you have links to the key studies? I’d be happy to read them.

Hey relaxed

Here are the seminal papers

Reprogramming to recover youthful epigenetic information and restore vision

Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma

https://journals.sagepub.com/doi/10.1089/cell.2023.0074

Reprogramming Factors Activate a Non-Canonical Oxidative Resilience Pathway That Can Rejuvenate RPEs and Restore Vision

Lifebiosciences links:

https://clinicaltrials.gov/study/NCT07290244

Interesting.

A few points though:

  1. They seem to be competitors with lifebiosciences

2.The pictures seem to be in vitro and they are not in their publications only on their website as far as i can tell, i may be wrong.

3.I think sinclairs lab would have done the same in vitro experiments plenty of times before going to in vivo in mouse and primates models and patenting osk.

They would have detected ipscs and teratomas easily.

So not sure how much weight to put on those pics.

But its gd news for us all that we are seeing multiple genes being identified.